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QUANTITATIVE METHOD OF MEASURING CANCER CELL UROKINASE
AND METASTATIC POTENTIAL
P The subject invention relates to a method for evaluating metastatic potential of
tumors by quantitative detection of urokinase and DNA.
The cell sampled for examination is analyzed for the presence of high levels of
urokinase and abnormal DNA using analytical flow cytometry and digital image
analysis. Other factors such as membrane associated urokinase, increased DNA
synthesis rates and certain receptors can be used in the method for detection of
potentially invasive tumors.
The novelty of the invention appears to lie in the unique measurement and
correlation of urokinase content to DNA content of cells to provide a
quantitative indication of the metastatic activity of the tumor, which indicates
likelihood of spread of the cancer from the primary tumor. No previous method
has been developed to accurately measure the intracellular urokinase content,
membrane-bound urokinase and cellular secretion levels and then correlate those
urokinase levels with DNA content, DNA synthesis, and other markers of aggressive
tumor growth to determine the metastatic potential in an individual patient.
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QUANTITATIVE METHOD OF MEASURING
CANCER CELL UROKINASE AND METASTATIC POTENTIAL
Origin of the Invention
The invention described herein was made by an employee of
the United States Government and may be manufactured and used
by or for the Government of the United States of America for
governmental purposes without the payment of any royalties
thereof or therefor.
Background of the Invention
I0 Tumor cells of some cancers secrete enzymes that break
down the intracellular matrix and invade adjacent tissues.
The production of serine protease enzymes such as plasminogen
activator enzymes have been observed in connection with the
metastasis of tumor cells into healthy tissues. Plasminogen
15 activator enzymes have been linked to cancer detection, using
assays of enzymes extracted from the tumor cells (Camiolo,
S.M., Markus, G. and Piver, M.S. 'Plasminogen activator
content of gynecological tumors and their metastases."
Gvnecoloqical Oncolouv 26: 364-373, 1987) or assays of
20 supernatants from tissue culture of the tumor cells. (Hasui,
Y. et al., "Comparative study of plasminogen activators in
cancers and normal mucosa of human urinary bladder." Cancer
Research 49: 1067-1070, 1989. Harvey, S.R., et al., "Secre-
tion of plasminogen activators byhuman colorectal and gastric
25 tumor explants." Clin. EXDI. Metastasis 6: 431-450, 1988.)
Urokinase-type plasminogen activator (urokinase or uPA),
a serine protease, is not produced in most normal cells,
except at low levels in certain types of normal kidney cells,
colon and gastric mucosa, and endothelial cells lining small
1
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arteries. Urokinase (uPA) can be present in the tissues in
several molecular forms. The inactive proenzyme (scuPA) is
composed of 411 amino acids. ScuPa is converted to the active
enzyme by cleavage at Lys.158 - Iie.159, loss of the Lys.158
5 and formation of the double chain, high molecular weight form
(HMW-uPA) that is 54 kDaltons. A low molecular weight form
(LMW-uPA) can also be formed by cleavage of the HMW-uPA at
Lys.135 - Lys.136 giving a 33KDa active enzyme.
The active urokinase enzymes convert plasminogen into
i0 plasmin, which in turn, dissolves intravascular fibrin blood
clots and intracellular fibrin matrix components as well as
activating collagenases, laminases, and other related enzymes
which are important to the anchorage and growth regulation of
cells. Urokinase is produced in a number of tumors such as
15 lung, colon, gastric, uterine, breast, brain cancer and
malignant melanoma. High levels of urokinase (>3.5 ug/mg of
total protein) extracted from breast tumor tissues is an
indicator for high risk of recurrence and shorter patient
survival times. Janicke, et al. Fibrinolvsis 4:69-78, 1990.
20 Data from these clinical studies showing that a) measurements
of uPA in plasma are of no value and that b) measurements of
uPA in cytosol fractions give some prognostic value (0.12
benign vs. 1.65 ng/ml in metastatic breast cancer) and c)
measurements of the uPA extracted from all of the tumor cells
25 by Triton-X i00 treatment have even more significance (0.23
vs. 3.21 ± 2.40 ng/mg of metastatic breast cancer). However,
the standard deviation (S.D.) of these measurements represents
± 65% for benign breast cancer and ± 75% for metastatic
tissues. Clearly, cell extractions cannot make the precise
30 distinctions that are necessary as to the presence or absence
of uPA, since the extractions are from tissues containing some
normal cells, some cancer cells that may have no (or very
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little) uPA and those that may have significant amounts of
uPA. (Schmidt, M. et al, "Tumour-associated fibrinolysis: the
prognostic relevance of plasminogen activators uPA and tPA in
human breast cancer." Blood Coagulation and Fibrinolvsis i:
5 695-072, 1990). Also cells from primary lung and colon tumor
produce more uPA than cells from metastatic tumors, but
different methods of extraction and assays give widely
variable results (Markus, G. et al., "Plasminogen activator
secretion of human tumors in short-term organ culture,
i0 including a comparison of primary and metastatic colon
tumors." Cancer Research 43: 55-7-5525, 1983.).
It recently has been shown in cancer cells that the HMW
active form of urokinase, bound to the tumor cell membrane, is
responsible for the local lysis of the extracellular matrix,
15 hence the tissue invasion mechanism for metastasis. (Hollas,
W., Blasi, F., and Boyd, D. "Role of urokinase receptor in
facilitating extracellular matrix invasion by cultured colon
cancer." Cancer Research 51: 3690-3695, 1991.). The unbound
uPA and the LMW form is not responsible for local dissolution
20 of extracellular matrix in the immediate vicinity of the
metastatic tumor cell. (Cubellis, M.V., Wun, T. and Blasi, F.
"Receptor-mediated internalization and degradation of uroki-
nase is caused by its specific inhibitor PAI-I." EMBO Journal
9: 1079-1085, 1990.). Thus the direct measurement of
25 membrane-bound urokinase is more important to the prognostic
accuracy than is measurement of all urokinase (membrane-bound
and free uPA) present in cells or in the tissue specimen.
Total urokinase has been measured from tumor tissue and
secretion by cultured explants. These are difficult to
30 quantitate from biopsy to biopsy, especially if the mea-
surements are made on a large group of cells. The data
obtained is an average value of all normal and cancer cells,
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rather than a measurement of each individual cell. However,
direct measurements of intracellular and extracellular
urokinase have not been made previously.
A DNA content histogram of normal cells shows a single
5 diploid peak (at GI phase) and a tetraploid peak (at G2+M
phase). In most tumors, abnormal DNA content of tumor cells
is detected as a second GI peak or multiple peaks. Abnormal
DNA (DNA aneuploidy) is considered as an independent indicator
of tumor aggressiveness and poor prognosis that is used to
I0 supplement cytopathology grading. Flow cytometry can be used
to measure total DNA content as shown in U.S. Patent No.
4,780,406, Dolbeare et al. entitled Flow Cytometric Measure-
ment of Total DNA and Incorporated Halodeoxyuridine issued
October 25, 1988, which is incorporated herein by reference.
15 Cells disassociated and prepared for flow cytometry can be
analyzed for cell cycle stage as well as DNA content simulta-
neously. Flow cytometer measurement of the percentage of
proliferating tumor synthesizing DNA (S-phase cells) is an
independent indicator of malignancy. High percentages (15 -
20 20%) of S-phase tumor cells usually indicates an aggressive
malignancy and usually correlates well with abnormally high
DNA content. The labeling index (LI) obtained by pulse-
labeling cells with DNA precursors represents the rate that
DNA is being synthesized in tumor cells. Usually, a LI > 4%
25 is associated with a higher probability of recurrent malignan-
cy. (Merkel, D.E. Dressler, L.G. and McGuire, W.L., "Flow
cytometry, cellular DNA content and prognosis in human
malignancy, w J, Clin. Oncolouv 5: 1690-1703, 1987.)
summary of the Invention
30 A method has been developed for quantitative detection of
urokinase and correlating the urokinase levels to the DNA
content and additionally to the DNA synthesis rate for evalua-
4
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tion of metastatic potential of tumor cells. First, the cells
to be examined and evaluated are selected. The cells can be
obtained from known tumor cell lines cultured for research
purposes, from tumor biopsies or cytological samples from
5 patients or any other source of tissue to be examined for
metastatic activity of tumor cells. The cell sample prepara-
tions are incubated with antibodies specific to urokinase in
order to directly measure its presence in the isolated cells
on a cell by cell basis. The sample of cells may be prepared
i0 in suspension for analysis by analytical cytometry techniques
such as flow cytometry, digital image analysis or sectioned
and prepared as histology slides for digital image analysis.
The intranuclear DNA also is labeled or stained (using labels
or staining including propidium iodide, 4,6-diamidine-2-
15 phenylindole, Hoechst 33258 and others known to those skilled
in the art) to allow quantitative measurements of DNA content.
Viable cells also can be pulse-labeled with DNA precursors,
BdUr, or IdUr for a specific uptake period, then incubated
with fluorescent-labeled antibodies against the precursor to
20 quantitatively measure the DNA synthesis rates in those cells.
Measurements of DNA and urokinase also are made on the same
cells. DNA and urokinase measurements, may be made essen-
tially simultaneously if flow cytometry is used, or sequen-
tially from the same source cell population.
25 The cells or histology sections are incubated with
antibodies or anti-antibodies specific for urokinase.
Antibodies or anti-antibodies to specific forms of urokinase
may also be used. The antibodies can be monoclonal or
polyclonal antibodies that bind specifically to urokinase.
30 Further, intracellular urokinase is measured as well as
extracellular urokinase which is outside or associated with
the cell membrane outer surface.
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The antibodies specific to urokinase may be labeled with
a fluorescent marker detectable by analytical cytometry
techniques. Also DNA content and synthesis rate based on DNA
stains or pulse-labeled uptake of DNA precursors is measured
5 by image analysis and flow cytometry. The same cell sample can
be measured for DNA content and urokinase by vital staining
the DNA and labeling the urokinase with a marker so that both
the DNA and urokinase can be measured simultaneously using
two-color image analysis or flow cytometry.
i0 The presence of urokinase, particularly the inactive
proenzyme scuPA and the high molecular weight form HMW, is
correlated to DNA content to determine if the profile of the
urokinase to DNA ratio is within a range indicating metastatic
activity. The cells are measured individually on a cell by
15 cell basis so that the population examined can be ranked to
determine whether a high percentage of the cells have high
urokinase and abnormal DNA levels that indicates metastatic
activity. Relatively high urokinase and abnormal DNA will
indicate the need for aggressive oncology, radiation or
20 immunologic cancer therapy and adjuvant treatment following
surgical excision of the tumor.
In addition to urokinase and DNA content, other factors
for evaluating metastatic potential can be used with the
method of this invention. DNA synthesis rates indicating
25 aggressive tumor growth can be measured as described above and
correlated with cell surface receptors for tumor growth
factors such as EGF and hormones such as estrogen and proges-
terone. Also, other antibody specific markers that may be
helpful in indicating the stage of tumor development may be
30 used in conjunction with this method. For instance a quanti-
tative measurement for plasminogen activator inhibitor,
urokinase receptor and other associated hormone receptors have
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been made with the urokinase measurements.
By establishing a correlation between urokinase and DNA
content and labeling for DNA synthesis rate a screening
process can be used to identify metastatic tumor cells. The
5 isolated tissue is examined for cells containing urokinase.
Initial urokinase measurements may be made directly with
fluorescent labeled antibodies or indirectly with anti-uPa
antibodies and fluorescent secondary antibodies or by assays
for enzyme activity or by other biochemical means. Cells
i0 without a significant amount of urokinase need not be examined
further. For samples with cells with higher than normal
urokinase, then DNA content is measured. If the urokinase
levels are high in cells with abnormal DNAcontent, the direct
measurement of extracellular, especially membrane-bound, and
15 intracellular urokinase content can be made. The correlation
between abnormal DNA content and extracellular urokinase would
then be made. Cells or populations of cells that do not meet
the initial screening criteria for metastatic potential do not
have to undergo the more intensive steps of direct measurement
20 for membrane bound and intracellular urokinase per cell. The
screening process can incorporate the other measurements used
in the method for evaluating the presence of metastatic
activity. The presence of urokinase receptors, plasminogen
activator inhibitors, tumor growth factors and membrane
25 associated hormone receptors also can be measured.
Heretofore, the mean urokinase content of tissue extracts
or culture supernatants generally measured as compared to
total protein has been examined to indicate potential for
metastatic decrease or tumor recurrence. The unique measure-
30 ment and correlation of urokinase content to DNA content of
the same cells or same sample can give a quantitative indica-
tion of metastatic activity of the tumor, which indicates
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immediate concerns about the spread of the cancer from the
primary tumor and therefore more aggressive post-operative
treatments. No previous method has been developed to accu-
rately measure the intracellular urokinase content, membrane-
5 bound urokinase and cellular secretion levels and then
correlate those urokinase levels with DNA content, DNA
synthesis, and other markers of aggressive tumor growth to
determine the metastatic potential in an individual patient.
Brief Description of the Drawings
I0 Figure IA is a graphic representation of DNA found in CS
glioma cells, measured by fluorescent flow cytometry, which
shows the DNA content relative to the stage of the cell cycle.
Figure IB is a two dimensional plot of the log fluo-
rescence from urokinase (ordinate) vs. the log fluorescence
15 from the DNA contained in the CS glioma cells, as measured by
flow cytometry.
Figure 2A is a graphic representation of DNA found in
HBR09 glioma cells, measured by fluorescent flow cytometry,
which shows the DNA content relative to the stage of the cell
20 cycle.
Figure 2B is a two dimensional plot of the log fluo-
rescence from urokinase (ordinate) vs. the log fluorescence
from the DNA contained in the HBR09 glioma cells, as measured
by flow cytometry.
25 Detailed Description of the Method
The method for analysis of the metastatic potential of
cells can be used for diagnostic, research, or any other
purpose. It is not the intent to limit the type of cell that
can be isolated and evaluated nor to limit the type of
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histological tissue that can be labeled with the fluorescent
anti-urokinase antibodies for measuring the urokinase in situ
in the tissue biopsy. The following is a general description
of the method including the preferred method. It is not
intended to disclose every mode to practice the invention, and
substitutions and modifications to the steps described herein
may be made without departing from the scope of the invention.
Antibodies can be formed against the two major molecular
forms of uPA using established methods of isolating the HMW-
i0 uPA or LMW-uPA urokinase protein then immunizing animals to
produce the antibodies. Typically, the uPA antigen is
isolated from human urine or cell culture medium by absorption
chromatography. Most commercial anti-uPA antibodies are
murine antibodies made against human urokinase. The commer-
15 cial antibodies (such as AD#394 and AD#3689 American
Diagnostica, Inc.) can detect the 54 kDA HMW-uPA or the 33
KDa LMW-uPA forms of uPA, but they cannot distinguish between
the 54 kDA HMW-uPA active and proenzyme scuPA molecular forms
(also 54 kDA). The HMW-uPA is used by the tumor cells to
20 rapidly invade adjacent tissue. Therefore, it is important to
distinguish between HMW-uPA with its proenzyme scuPA and LMW-
uPA. The commercial anti-uPA antibodies can inhibit the
normal enzymatic activation of plasminogen to plasmin.
Presently, none of the commercial anti-uPA antibodies are
25 specific for detection of the actual cleavage sites where
activation of the proenzyme (scuPA) occurs. Plasmin converts
scuPA to HMW-uPA. Measurements of scuPA may be performed by
preincubation of duplicate samples with and without plasmin
and measuring the presence of HMW-uPA in both samples and
30 quantifying the difference attributable to scuPA.
Anti-uPA antibodies can be used as the primary anti-body
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in sandwich assays or in permeabilized cytology preparations,
wherein either the anti-uPA antibodies can be fluorescently
labeled or a secondary, fluorescent labeled, antibody can be
attached to the anti-uPA primary antibody; thus permitting
5 fluorescence image analysis or laser activated flow cytometry
analysis to determine the amount of the intracellular and
membrane bound urokinase in each cell. Also the anti-uPA
antibodies themselves can be conjugated with markers having
detectable physical or chemical properties. The markers are
i0 well known in the field of immunoassays. The preferred method
utilizes markers with detectable light emissions by fluores-
cence, phosphorescence or luminescence, however, markers that
absorb light, such as peroxidase, and radioactive labels can
also be used. Primary and secondary detection of the antibod-
15 ies may be useful in the invention with different types of
cell or tissue samples
The cells to be examined are first isolated. The cells
may be from a tumor, fine-needle biopsy or cytological sample.
The anti-uPA antibodies are incubated with the cells. In a
20 preferred method for examination of intracellular and mem-
brane-bound extracellular urokinase, the cells are labeled
with fluorescent markers for digital image analysis. Using
digital image analysis the anti-uPA antibodies can be located
and quantitatively measured in both the cytoplasm and where
25 the urokinase is bound to the cell membrane. These measure-
ments are used statistically to give the relative distribution
and absolute concentrations of membrane-bound and cytoplasmic
urokinase in biopsy cells. This data can then be used to
statistically compare the urokinase levels and distribution in
30 those cells with tumor cells from other patients, thus giving
a quantitative benchmark as to the metastatic state of those
tumors in each individual patient. This data also can be used
I0
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in retrospective studies where the time to reoccurrence,
degree of metastasis and morbidity are known. Cumulative data
on patients can then be used to provide a prognostic indicator
of the degree of active metastasis in primary tumors.
5 Another alternative method for analysis of cellular
urokinase is by flow cytometry. The membrane-bound urokinase
can be measured directly by incubating the cells with the
fluorescent labeled antibodies against the different molecular
forms of urokinase. Whereas, the intracellular urokinase can
i0 only be measured after the cell wall has been partially
permeated bychemical or electro-chemical poration techniques.
Then the anti-uPA antibodies can penetrate the cell and attach
to the urokinase in the cytoplasm. Laser activated flow
cytometry can be used to determine uPA content per cell. The
15 cells containing uPA can be sorted as they pass through the
flow cytometer and selected for uPA content. The selected
cells are further examined by digital image analysis for
cytoplasmic or intracellular uPA and extracellular, membrane
bound uPA. A large population of cells can be examined using
20 flow cytometry and fluorescent antibodies as a screening
method prior to digital image analysis.
An alternate preferred method involves the parallel
measurement of membrane bound urokinase, intracellular
(cytoplasmic) urokinase levels using digital image analysis of
25 the fluorescent micrographs and correlations with DNA content
and DNA synthesis rates as measured by flow cytometry or image
analysis. Abnormal DNA levels are related to the aggressive
growth of the tumor cells.
If the cells are not actively metastasizing they have no
30 urokinase or very low levels of urokinase including low
amounts of membrane-bound urokinase and high levels of
Plasminogen Activator Inhibitor (PAI-I and/or PAI-2). These
ii
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are characteristic of non-invading, non-metastasizing primary
tumors or metastatic tumor cells that already are well
established at the metastatic site. The tumor cells that are
actively invading adjacent tissues and metastasizing are
5 characterized by high levels of membrane-bound HMW-uPA or
scuPA type urokinase, abnormal levels of DNA and low levels of
PAI-I. The quantitative measurements of DNA, urokinase and
PAI-I enable precise comparisons to establish the unique
metabolic state of the tumor cells that are preparing for or
i0 actively metastasizing.
The method of this invention also includes the step of
measuring the DNA content in the cells isolated from Patient
biopsies. The nuclear DNA content can be determined by
labelling with vital stains such as propidium iodide (PI),
15 Hoeschst stain, DAPI or by antibodies reactive to DNA or a DNA
precursor as described in U.S. Patent No. 4,780,406, issued
October 25, 1988, to Dolbeare and Gray which has been incorpo-
rated by reference herein. Urokinase expression and secretion
is regulated by certain cytokines and hormones. It has been
20 shown that the recurrence of breast and other cancers is
related to the number of estrogen (ER) and progesterone
receptors (PgR) found on the surface of the tumor cells. The
use of fluorescent antibodies against ER and PgR enables the
simultaneous measurement of receptor density on the cell
25 surface to be compared with the DNA and the urokinase levels
in normal and tumor cells. The hormone receptor levels can be
measured either by flow cytometry or digital image analysis
and then directly compared with the urokinase levels. The DNA
content is preferably measured using flow cytometry, but also
30 can be measured by image cytometry.
Byusing different fluorescent labels or markers that can
be measured at essentially the same time at two or more
12
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different wavelengths the same cell population that is
examined for urokinase can be simultaneously assayed for PAI,
DNA content, DNA synthesis rate or hormone receptors. For
example, fluorescent antibodies to both the DNA or DNA
5 precursors and urokinase forms can be used with different
emission characteristics, thus the flow cytometer can simulta-
neously measure two or more color fluorescence of the two or
more antibodies. Digital image capture also can be performed
at multiple wavelengths thus enabling measurements of more
i0 than one intracellular protein or membrane receptor and DNA in
the same tissue specimens.
Digital analysis measurement of the amount of urokinase,
in the cytoplasm or membrane-bound, also can be used with the
measurement of DNA content by flow cytometry. The identical
15 cell population is not necessarily used for each analysis,
however, since aliquot samples are used from the same cells
that were isolated from the surgical biopsy.
Another alternative method also measures the synthesis
rate of DNA in the cells by pulse labeling with DNA precursor
20 amino acids (BdUR or IdUR) and then labeling with fluorescent
antibodies against the DNA precursor to determine the amount
of incorporation per unit time. (Gratzner, H. G. and Leif, R.
C. "An immunofluorescence method for monitoring DNA synthesis
by flow cytometry." ¢ytometrv 6: 385-389, 1983.). The DNA
25 synthesis rate can either be measured by flow cytometry or
fluorescence image analysis and thus compared directly to the
levels of urokinase in the tumor cells.
Another alternative method is measurement of urokinase
using fluorescence image analysis of de-paraffinized or frozen
30 histology sections from biopsy tissues. DNA can be measured
simultaneously using a vital fluorescent stain (PI or DAPI) or
fluorescent labeled antibodies against BdUR or IdUR that emits
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fluorescence at a different wavelength than does the labeled
anti-uPA antibodies. Supporting flow cytometry data can be
obtained from thick sections from the tumor specimens,
whereupon the cells are dissociated, treated with RNAse, the
5 nuclei freed from the cytoplasm and flow cytometry performed
on the nuclei. This data is then compared to the urokinase
levels or image analysis data on cells taken from the same
biopsy tissue.
To illustrate the method of this invention the corre-
lation of urokinase on a cell by cell basis and DNA content
have been examined in two glioma cell lines obtained from
surgical biopsies removed from two different patients (CS and
HBR09) with brain tumors. Comparisons were made among: i)
autofluorescence measured in cells treated with a non-specific
15 immunoglobin (IgG) as controls, 2) green fluorescence measured
from cells treated with FITC-labeled antibodies against
urokinase, and 3) red fluorescence measured from the DNA in
the same cells stained with propidium iodide, using cell
samples that were disassociated for flow cytometry. The CS
20 cells are less invasive and metastatic brain tumor cells than
HBR09 cells.
The DNA was measured by flow cytometry for the CS cells
and HBR09 cells and Figures IA and 2A show the DNA content for
each cell type in various stages of the cell cycle. The same
25 cells were measured by flow cytometry for HMW-uPA (with
commercial anti-uPA antibodies HMW-uPA that cannot distinguish
between scuPA and active HMW-uPA). Figure IB illustrates the
correlation of the uPA content vs. the DNA content in the CS
cells, while Figure 2B illustrates a different pattern of uPA
30 content vs. the DNA content in the more invasive HBR09 cells.
Table 1 summarizes the presence of DNA and uPA in the CS and
HBR09 tumor cell lines. It should be noted that the differ-
i0
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ence in uPA content between the CS and HBR09 cell types is
more pronounced when the cells are in the resting cells
(GI/G0) compared to the those cells that are active synthesiz-
ing DNA and dividing (S & G2+M). In other tumor cells the
5 difference may be greater in S and G2+M phases.
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Table 1 is a summary of simultaneous flow cytometry
measurements using fluorescent markers for DNA and uPA in IgG-
treated control cells; CS cells (illustrative of a less
invasive glioma tumor); and HBR09 cells from a more invasive
5 tumor. DNA values are based on the mean fluorescence from
propidium iodide (pI) stain while uPA values are based on
FITC-labeled, anti-uPA antibodies that bind to HMW-uPA and
scuPA. The DNA and uPA values for the IgG controls are mean
measurements of the non-specific autofluorescence measured
i0 from the cells in the PI and FITC bandpass regions, respec-
tively. The control cells had very little uPA, especially in
the resting phase (GI/G0). The CS cells in GI/G0 contain 1.7
times more DNA than the HBR09 cells, but the HBR09 cells
contain 6.4 times more uPA. The same relationship is present
15 in the S + G2÷M phases, however, the HBR09 cells contain only
3.3 times more uPA than do the CS cells.
Figures IA and 2A are graphic representations of the cell
distribution data for DNA content, obtained from the flow
cytometer printouts and summarized in Table i. The legends
20 show the relative distribution of the cells in the GI/G0, S,
and G2+M phases of the cell cycle. Figure IA is a semilog plot
of the CS cell number vs. the DNA content, where the DNA is
represented by the log fluorescence from PI staining (abscis-
sa). Figure 2A is a semi-log plot of the cell number vs. the
25 DNA content for the HBR09 cells.
Figures IB and 2B are graphic representations of the uPA
and DNA content for the CS cells and HBR09 cells, respective-
ly, measured by two-color flow cytometry as summarized in
Table i. DNA was measured by the DNA specific fluorescent dye
30 propidium iodide and uPA was measured by FITC-labeled anti-
urokinase antibodies. In Figures IA and 2A zone 1 is the
fluorescence measurement for the DNA content in the cells at
17
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GI/G0, zone 2 is for the cells in S+G2÷M, and zones 3 and 4
represent low-level background /autofluorescence levels below
the gating value selected from identical runs with negative
controls. In general, the DNA fluorescence for the HBR09
5 cells in the S and G2÷M phase (Fig. 2B, zone 2) is higher than
the CS cells (Figure IB, zone 2). Furthermore, the distribu-
tion of HBR09 cells containing high levels of uPA in the
resting phase (Figure IB, zone I) is more focused than the CS
cells (Figure 2B, zone i.) Eighty-eight percent of the HBR09
i0 cells in the resting phase and 96% of the cells in S and Ga÷_
(zone 2) have high levels urokinase in contrast to the CS
cells where 42% in the resting phase and only 54% of the cells
in S and G2+. have significant levels of urokinase. Also the
mean content of uPA per HBR09 cell is greater than the CS
15 cells in all phases of the cell cycle.
Flow cytometry can be used for disassociated cell samples
to initially screen for the abnormal DNA content and uPA
profile indicating aggressive tumors. Cells with abnormal DNA
and high levels of uPA particularly in the S phase merit
20 attention for potentially aggressive tumor tissue and further
examination by digital image analysis. However, the analysis
by flow cytometry using this method may be sufficient with
existing pathological procedures and tests to make a determi-
nation on treatment of a dangerously malignant tumor.
25 Image analysis was performed on fluorescent uPA antibod-
ies in CS and HBR09 cells. Image analysis can quantify the
presence of uPA by measuring the fluorescence emitted by
labeled antibodies that are bound directly to uPA. Table 2
illus_rates the comparison of flow cytometry analysis and
30 digital image analysis of fluorescent-labeled uPA antibodies,
wherein each sample of glioma cells were split into two groups
for parallel assays of uPA. Table 2 shows the high levels of
18
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uPA in CS and HBR09. However, in comparison HBR09 has much
higher levels of uPA than CS as confirmed by both flow
cytometry and image analysis. Note that the image analysis
method show a greater ratio of uPA in the HBR09 cells as
5 compared to the CS cells and that the standard deviation of
the mean fluorescence is smaller (8-9%) compared to the flow
cytometry data (10-35%) on the same cells.
19
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TABLE 2
COMPARISON OF UROKINASE IN CONTROL AND BRAIN CANCER CELLS
Q$ING FLUORESCENT-LABELED uPA ANTIBODIES
CELL MEAN MEMBRANE-
LINE FLUORESCENCE S.D. BOUND uPA S.D.
IgG (Control) 2.05 0.3 -FLOW
CYTOMETRY
CS 6.13 0.i -
HBR09 32.25 11.3
RATIO HBR09/CS = 5.26/1"
IgG (Control) 1.86IMAGE
ANALYSIS
CS
HBR09
II .3
74.1
RATIO HBR09/CS = 7.56/1
0,1
0.76 78.3
(8%)
6.34 821.9
(9%)
HBR09/CS = 10.5/1
3.41
(4%)
47.8
(6%)
"RATIO HBR09/CS = 7.4 after autofluorescence is subtracted
20
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Image analysis has the further benefit of measuring the
membrane bound uPA. Using the method of this invention, a
determination of the presence of membrane bound uPA is made
when indicated. The fluorescent microscope can be focused on
5 different levels within each cell before the images are
digitized, thus it can be distinguished if the uPA is on the
cell surface or within the cell cytoplasm. Digital levels can
also be selected so that areas of the cell surface or cyto-
plasm emitting a given fluorescence intensity can be measured
i0 and labeled, thus providing quantitative data and a visual
reference for use with other cytopathological evaluations.
The presence of uPA at the membrane indicates a tumor cell
that is actively invading adjacent tissues or migrating to a
remote site to establish a new metastatic tumor. In Table 2
15 the membrane bound uPA is significantly higher in the more
invasive HBR09 than in the CS cells. The use of image
analysis is precise and can be used on tissue such as biopsies
on slides in which the cells have not been disassociated.
Image analysis can also be used to quantify they different
20 forms of urokinase in the same cells by using different
fluorescent antibodies for different forms of urokinase.
The method also includes screening for the presence of
plasminogen activation inhibitors (PAI) PAI-I and PAI-2.
Antibodies specific to PAI-I and PAI-2 with a fluorescent
25 label may be used. An aggressive tumor will have higher
levels of abnormal DNA (tetraploid or greater) while metastat-
ic cells will have low levels of PAI-I or PAI-2 and high
levels of uPA.
Membrane bound PAI-I and PAI-2 measurements can also be
very important since the PAI can compete with the uPA for
binding to the uPA receptor on the tumor cell surface. The
method can also incorporate fluorescent antibodies specific
21
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for the uPA receptors on the cell surface. Comparison of the
DNA content, DNA synthesis rate, uPA content, membrane-bound
uPA, PAI and uPA receptor density in tumor cells can give the
clinician much clearer insight into the metastatic potential
5 of each tumor that is biopsied. The combined method of
cytology testing described herein is required to provide a
systematic way of acquiring the required data and accuracy
needed for determining the true metastatic potential of a
particular tumor. This information can provide the basis for
i0 custom therapeutic regimens that are designed for each cancer
patient's circumstance at the time of the biopsy.
The examples and methods described herein exemplify the
invention and are not intended to limit the scope of the
invention in any way. Other methods of practicing the
15 invention will be apparent to those skilled in the art.
22
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ABSTRACT
The metastatic potential of tumors can be evaluated by
the quantitative detection of urokinase and DNA. The cell
sample selected for examination is analyzed for the presence
of high levels of urokinase and abnormal DNA using analytical
flow cytometry and digital image analysis. Other factors such
as membrane associated urokinase, increased DNA synthesis
rates and certain receptors can be used in the method for
detection of potentially invasive tumors.
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